Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib in newly diagnosed FLT3-ITD (+) AML
NCT02668653Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2016
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Chemotherapy plus quizartinib with Chemotherapy plus placebo (2 arms). Primary endpoint: Overall Survival up to 3 years. Started Sep 2016; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02668653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02668653.